Company intelligence / Profile preview
Prothya Biosolutions
Amsterdam, Netherlandsprothya.com ↗
- Ownership
- Private
- Employees
- ~646
- Development stage
- Other
01
Overview
Prothya Biosolutions produces commercial plasma-derived medicines such as Cofact, Nanogam, and Albuman. The company also has clinical-stage programs including human apotransferrin for congenital atransferrinemia in Phase III trials. It processes around three million liters of plasma annually for international partners.
- Therapeutic areas
- OtherHematologyImmunologyRare Diseases
- Modalities
- ProteinPlasma-derived medicinal productsRecombinant protein
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Erasmus MC and other academic collaborators on clinical studies/programs
Beyond the preview
Go deeper on Prothya Biosolutions.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Prothya Biosolutions.